Real-Time Monitoring of Implantable Pumps

Abstract

mplantable drug delivery pumps administer insulin, intrathecal baclofen, intrathecal morphine, chemotherapeutic agents, and other therapeutics directly to target anatomical sites over months or years of continuous operation. The clinical consequences of pump malfunction range from therapy interruption to life-threatening overdose, and the diagnostic challenge of distinguishing true device failure from underlying disease progression has historically depended on clinical assessment, blood levels, and invasive device interrogation at scheduled follow-up visits. Real-time monitoring of implantable pumps through telemetry, sensor integration, and algorithmic anomaly detection addresses this diagnostic gap by providing continuous device performance visibility to clinicians and patients, enabling earlier detection of device malfunction, catheter occlusion, battery depletion, and delivery accuracy drift than periodic assessment provides. This study presents the Implantable Pump Monitoring Assessment Framework (IPMAF), evaluating five monitoring approaches -- embedded telemetry with periodic data upload (ETM-PDU), continuous cloud-based pump telemetry with threshold alerting (CCT-TA), multi-sensor fused monitoring with AI anomaly detection (MSF-AI), closed-loop integrated sensing with delivery algorithm adjustment (CLI-DAA), and federated cross-patient pump performance analytics (FCP-PPA) -- across four implantable pump contexts: insulin pumps, intrathecal baclofen/morphine pumps, hepatic arterial chemotherapy pumps, and emerging closed-loop neurological drug delivery systems. Performance was scored using the Pump Monitoring Effectiveness Score (PMES), a weighted composite of fault detection sensitivity (0.30), alert lead time (0.20), false alert management (0.20), patient-provider workflow integration (0.15), and privacy and data security (0.15). Multi-sensor fused monitoring with AI anomaly detection achieved the highest PMES (0.887) through the best fault detection sensitivity (0.940) and strong alert lead time (0.920). Closed-loop integrated sensing ranked second (0.878) with the best alert lead time (0.940). Continuous cloud-based telemetry (0.872) provides broadly applicable monitoring. Embedded telemetry (0.851) remains the regulatory baseline. Federated cross-patient analytics (0.839) supports population-scale performance surveillance